Payment overview · 2025
General Payments
$1,177.66
59 reported records · 23 companies
Healthcare provider profile · identity verified
Amy E Hull, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · POTTSTOWN, PA · NPI 1710943063
Verified facts
What the public records show
CMS Open Payments records show Amy E Hull, CRNP received $1,177.66 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $210.46 | 17.9% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $160.26 | 13.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $147.50 | 12.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.10 | 8.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.99 | 7.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.88 | 4.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.39 | 3.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.90 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.77 | 2.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.04 | 2.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $26.49 | 2.2% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.51 | 2.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.97 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.94 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.79 | 2.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.33 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.40 | 2.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.83 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.37 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.46 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.43 | 1.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.84 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.01 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,177.66 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $100.21 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $99.31 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.13 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.04 | 5 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $72.22 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.20 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.02 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $60.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.36 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.88 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $42.22 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $3.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 110 |
| Losartan Potassium | Losartan Potassium | 293 | 88 |
| Lisinopril | Lisinopril | 292 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 91 |
| Metformin Hcl | Metformin Hcl | 199 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 61 |
| Simvastatin | Simvastatin | 166 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 52 |
| Sertraline Hcl | Sertraline Hcl | 137 | 40 |
| Lorazepam | Lorazepam | 135 | 40 |
| Gabapentin | Gabapentin | 125 | 38 |
| Omeprazole | Omeprazole | 125 | 41 |
| Tramadol Hcl | Tramadol Hcl | 125 | 44 |
| Alprazolam | Alprazolam | 124 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 40 |
| Furosemide | Furosemide | 119 | 50 |
| Montelukast Sodium | Montelukast Sodium | 118 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 37 |
| Ozempic | Semaglutide | 99 | 16 |
| Eliquis | Apixaban | 94 | 22 |
| Meloxicam | Meloxicam | 92 | 32 |
| Azithromycin | Azithromycin | 82 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 30 |
| Atenolol | Atenolol | 68 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | 24 |
| Jardiance | Empagliflozin | 61 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 25 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 16 |
| Allopurinol | Allopurinol | 56 | 17 |
| Lovastatin | Lovastatin | 56 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 17 |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 21 |
| Methylprednisolone | Methylprednisolone | 47 | 39 |
| Fenofibrate | Fenofibrate | 45 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 33 |
| Prednisone | Prednisone | 43 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 26 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Celecoxib | Celecoxib | 36 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Trulicity | Dulaglutide | 34 | 11 |
| Famotidine | Famotidine | 33 | 14 |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 11 |
| Effexor Xr | Venlafaxine Hcl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 14 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Fluconazole | Fluconazole | 22 | 13 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 16 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,177.66 · 59 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, IQIRVO, JARDIANCE, Kerendia, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SYNTHROID, Symbravo, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error